These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21419857

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.
    Morimoto H, Nakao K, Fukuoka K, Sarai A, Yano A, Kihara T, Fukuda S, Wada J, Makino H.
    Nephrol Dial Transplant; 2005 Dec; 20(12):2775-82. PubMed ID: 16221689
    [Abstract] [Full Text] [Related]

  • 46. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S, Ueda S, Okuda S.
    Med Hypotheses; 2007 Dec; 69(4):922-4. PubMed ID: 17368960
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY, Sahin E, Koçak H, Tuncer M, Gümüşlü S.
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R, Cibulka R, Rajdl D, Racek J.
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.
    Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D.
    Circulation; 2004 Jan 20; 109(2):172-7. PubMed ID: 14662708
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN, Sousa LP, Mota AP, Rios DR, Dusse LM.
    Clin Chim Acta; 2015 Feb 02; 440():36-9. PubMed ID: 25444745
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.